Clinical Trial Update: Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update assesses whether dutasteride (Avodart) can extend time to progression in men with low-risk, localized prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Avodart (dutasteride)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Prostate | Phase 4 | Status: COMPLETED | Results posted: 2011-06-14